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Abstract
Rare diseases are an important public health issue with high unmet need. The introduction of the EU Regulation on
orphan medicinal products (OMP) has been successful in stimulating investment in the research and development
of OMPs. Despite this advancement, patients do not have universal access to these new medicines. There are many
factors that affect OMP uptake, but one of the most important is the difficulty of making pricing and reimbursement
(P&R) decisions in rare diseases. Until now, there has been little consensus on the most appropriate assessment criteria,
perspective or appraisal process. This paper proposes nine principles to help improve the consistency of OMP P&R
assessment in Europe and ensure that value assessment, pricing and funding processes reflect the specificities of rare
diseases and contribute to both the sustainability of healthcare systems and the sustainability of innovation in this field.
These recommendations are the output of the European Working Group for Value Assessment and Funding Processes
in Rare Diseases (ORPH-VAL), a collaboration between rare disease experts, patient representatives, academics, health
technology assessment (HTA) practitioners, politicians and industry representatives. ORPH-VAL reached its
recommendations through careful consideration of existing OMP P&R literature and through a wide consultation with
expert stakeholders, including payers, regulators and patients. The principles cover four areas: OMP decision criteria, OMP
decision process, OMP sustainable funding systems and European co-ordination. This paper also presents a guide to the
core elements of value relevant to OMPs that should be consistently considered in all OMP appraisals. The principles
outlined in this paper may be helpful in drawing together an emerging consensus on this topic and identifying areas
where consistency in payer approach could be achievable and beneficial. All stakeholders have an obligation to work
together to ensure that the promise of OMP’s is realised.
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Value assessment, Guidelines
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Background
The European Union (EU) regulation on Orphan Medi-
cinal Products (OMPs) EC 141/2000 has been vital for
stimulating investment into OMP research and develop-
ment (R&D), furthering an EU-wide aim of ensuring that
patients with rare diseases have equity of access to
effective treatment [1, 2]. To date, the European
Medicines Agency (EMA) has authorised 129 OMPs and
1,435 as yet unapproved products have OMP designa-
tion [3]. Rare diseases are an important public health
issue and it is important that patients with these diseases
have access to safe and effective therapies in the same
way as others suffering from more common diseases [4].
Once regulatory authorisation has been granted to an
OMP by the EMA, it is essential for patients to benefit
from it within the shortest timeline and this should be
consistent across Europe. Whether this goal is achieved
is influenced by the pricing of these therapies and by the
mechanisms used by national healthcare decision-
makers to assess, reimburse and fund them [1, 2, 4–7].
A 2009 study found that, of 43 EMA-approved OMPs,
the proportion reimbursed varied from 56 to 91% across
seven Western-European countries [1, 8]. Another
evaluation of 10 European countries observed a differ-
ence in reimbursement between countries according to
income level, with France, Netherlands and Denmark re-
imbursing 90% of 60 authorised OMPs, while Spain,
Greece and Romania reimbursed only one-third [9].
P&R processes for OMPs are particularly challen-
ging due to the inherent characteristics of rare dis-
eases and the scarcity of knowledge and expertise on
the natural history of these conditions [10, 11]. Clin-
ical trial development is also complicated due to
small and typically heterogeneous patient populations,
resulting in difficulties in patient identification and
recruitment, and lack of surrogate end-points to
predict longer term outcomes [12]. Therefore health
technology assessment (HTA) agencies often have to
assess OMP value – the benefit from treatment for
patients, healthcare systems and society – in the pres-
ence of evidential uncertainty [10, 11].
The small size of the target patient population – OMP
regulation in Europe stipulates a prevalence of less than
5 in 10,000 [13] – means that the per-patient price of
OMPs is higher than for medicines for more common
conditions [14]. As a consequence, OMPs assessed in
systems that use cost-effectiveness analysis have often
failed to meet accepted thresholds, particularly where
the prevalence is at the lower end of the spectrum of
rare diseases [11, 15]. Uncertainty about the true size of
rare disease patient populations creates financial risk for
payers and compounds broader concerns about the on-
going cost of funding the growing number of treatments
for rare diseases [5, 16, 17].
Some HTA bodies and payers have reacted to these
challenges by creating supplementary OMP-specific as-
sessment mechanisms (e.g. NICE Highly Specialised
Technology Programme in England and the Life Savings
Drugs Program in Australia) or by adapting existing
P&R processes (e.g. OMP special status in benefit assess-
ments in Germany and the PACE process at the Scottish
Medicines Consortium) [18, 19]. More often, decisions
regarding OMPs are made following the same process as
for other medicines.
The diversity of P&R pathways for OMPs across
European countries can represent a challenge to all manu-
facturers of medicines, and this is particularly true for
OMPs. While there is some consistency in the core clinical
information considered by HTA agencies, there are consid-
erable disparities in how data is interpreted, the use of eco-
nomic analysis, the perspective of the evaluation and the
extent to which patients and healthcare professionals
(HCPs) are involved, amongst other factors [11, 18, 20, 21].
These differences in assessment methodology partly
reflect a lack of consensus amongst policy makers on the
optimal P&R framework for OMPs and how to over-
come the challenges that rare diseases represent to HTA
agencies. Many European countries are reviewing P&R
processes for OMPs, providing an opportunity to seek
closer alignment on the fundamental aspects of such
systems [22, 23].
In this paper we propose nine principles to help im-
prove the consistency of OMP P&R in Europe and ensure
that it reflects the inherent characteristics of rare diseases.
The principles cover issues relating to value assessment,
P&R, and funding processes for OMPs, grouping them in
four parts: decision criteria, decision processes, sustain-
able funding and European co-ordination.
Moreover, to help improve consistency in the decision
criteria used to assess the value of OMPs between coun-
tries, we propose a set of core elements that together
constitute the value of an OMP. This paper does not
represent an attempt to define a single P&R framework
for European countries, but rather to propose underlying
principles that should be common to all, regardless of
the mechanism used in each country to make decisions.
The principles described herein are recommendations
from the 15 authors of this article, who are designated
as the European Working Group for Value Assessment
and Funding Processes in Rare Diseases (ORPH-VAL).
This Working Group is a collaboration between rare dis-
ease experts across seven European countries, including
HTA practitioners, physicians, patient representatives,
academics, politicians and industry representatives. A
detailed description of each Working Group member’s
experience relevant to this topic is provided in the dec-
laration section. The experts were selected to achieve a
breadth of geographical and disciplinary perspective and
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based on their active involvement in the field of rare dis-
eases and willingness to participate in the initiative on a
voluntary basis. ORPH-VAL reached its recommended
principles through an iterative process of assessment of
existing OMP guidelines and frameworks, identification
of core themes, formulation of draft principles, internal
and external review, and subsequent refinement. The
Working Group members participated in five workshops
(two face to face, three via teleconference) between June
2015 and September 2016 (Fig. 1). Wherever possible,
ORPH-VAL has built upon, or aligned with, outputs
from existing initiatives in this area, such as the Mecha-
nisms of Co-ordinated Access to Orphan Medicinal
Products (MoCA-OMP) and EUnetHTA Joint Action 2.
The core elements of OMP value were selected from a
systematic review of proposed frameworks for rare dis-
eases and non-rare diseases [24]. Table 1 shows the
frameworks reviewed by ORPH-VAL.
Elements of value proposed in the literature were pre-
sented to the Working Group according to the fre-
quency of occurrence and grouped by theme (e.g.
disease-related, clinical, economic) and by perspective
(patient, healthcare system, society). From this starting
point, ORPH-VAL members were split into two groups
which separately prioritised the core elements, before
seeking consensus between the groups. Two sets of ele-
ments were considered: 1) elements that inform on the
intrinsic value of an OMP and as such should be
accounted for by decision making committees during
the deliberative process; 2) elements that are beyond
product value but are likely to inform or influence the
P&R decision.
ORPH-VAL refined its principles through feedback from
other European rare disease experts and stakeholders
(Fig. 1). A draft version of the principles was presented
and debated during the EURORDIS Multi-Stakeholder
Symposium on the 24th of February 2016. A public con-
sultation of the draft principles was organised through
EURORDIS and publicised through OrphaNews on the
22nd March 2016. Interested participants were invited to
complete an online survey and provide their comments
on the document. Finally, ORPH-VAL had an opportunity
to present and discuss the principles with the MoCA-
OMP Group in September 2016. Feedback from all
commentators was collated into themes for consider-
ation by ORPH-VAL before being incorporated into a
second draft of the principles. The nine principles are
summarised in Fig. 2.
Principles on OMP decision criteria
Rare diseases have particular characteristics beyond
the small number of patients affected. They often impact
patients from birth, affect multiple organ systems, are
severely disabling, can greatly reduce life expectancy and
impair physical and mental abilities [37, 38]. These
Fig. 1 Process through which the Principles were developed. MoCA-OMP: mechanism of coordinated access to orphan medicinal products;
MCDA: multi-criteria decision analysis; P&R: Pricing and reimbursement; TC: teleconference
PRINCIPLE 1: OMP assessment should consider all relevant elements
of product value in an appropriate multi-dimensional framework
a) Decision-makers should consider OMP value from the perspective of
patients, the healthcare system and wider society
b) While the choice of value elements that are used to assess OMPs should
be country specific, ORPH-VAL has proposed a set of core elements that
should be common to all health systems (Fig. 3)
c) HTA agencies and payers should make explicit which elements of value
they prioritise, how the rarity of a disease influences their assessment,
and how societal preferences are incorporated into their decisions
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impairments affect health-related quality of life (HRQoL)
and can impact an individual's ability to benefit from
education and secure employment [39]. In a survey of
2,500 patients with chronic diseases, patients with rare
disorders had the worst experience in terms of loss of
social and economic opportunities and of access to med-
ical care [39].
Rare diseases also often have a disproportionate im-
pact beyond the patient. Many rare diseases are gen-
etic, meaning more than one member of a family can
be affected [39]. Rare diseases also pose a consider-
able burden on caregivers [37, 39]. The severity of
rare diseases means patients often require intensive
care, usually from a family member, which reduces
their ability to work. The lack of specialist support
and information on the disease increases the burden
for patients and their families. At a wider level, rare
diseases require substantial healthcare and social care
system resources [38, 40–42]. Given the multi-
dimensional nature of the burden of rare diseases and
the wide range of stakeholders affected, it is import-
ant that decision makers assess the value of OMPs
holistically, including the perspectives of patients, the
healthcare system and wider society (including family
and carers).
The elements that are considered within P&R de-
cisions vary across European countries [43]. ORPH-
VAL has proposed a set of core elements it believes
should be common to all systems (Fig. 3; a detailed
description of the elements and explanation of the
terms used is included in Additional file 1). The ele-
ments described in Fig. 3 represent proposed do-
mains of value. ORPH-VAL did not seek to define
metrics for how these elements should be measured,
nor value thresholds or weights indicating the rela-
tive importance of different elements. Such factors,
which relate to the creation of societal value, should
be informed by, and aligned with, societal prefer-
ences of the population in the respective country.
While information on potential international vari-
ation in societal value judgments is still limited,
there is a growing body of literature documenting
the relevance and breadth of societal preferences
[44, 45].
Fig. 2 Summary of Principles for value assessment and funding processes in rare diseases
Annemans et al. Orphanet Journal of Rare Diseases  (2017) 12:50 Page 5 of 15
With a recognition of the importance of transpar-
ency in the evaluation process, P&R frameworks
should be clear about the elements of value that are
considered within the value assessment process and
their relative importance in determining the overall
decision [46, 47]. It should be explicit how these de-
cisions are informed so as to ensure legitimacy and
to provide clear guidance to OMP developers about
the types of products that society wishes them to
develop [48].
Multi-criteria decision analytic (MCDA) frameworks
have been proposed for rare diseases [21, 25, 26, 29, 30].
These frameworks have the advantages of providing
sufficient flexibility to incorporate all value elements of
importance and, as shown in a pilot study of a rare dis-
ease MCDA framework, are capable of incorporating
different stakeholder perspectives [21]. In contrast,
where cost-effectiveness frameworks have been used to
assess OMPs, they have often failed to be sufficiently
flexible to capture all relevant elements and perspec-
tives [49–51].
The OMP value assessment process, as described in
Principle 1, should form the basis of P&R decisions.
These two components – value assessment and P&R ap-
praisal – are often undertaken separately and consecu-
tively in many European systems, such as in France and
Germany [52, 53]. In order to translate an assessment of
value into a P&R decision, it is necessary to interpret the
added value generated by a new OMP relative to an ap-
propriate price benchmark. The P&R decision should
therefore consider the value for money of a new OMP in
light of price precedents for other specialist medicines
that offer comparable value. These comparator products
should share similar fundamental characteristics to the
Fig. 3 Guide to core elements of value relevant to pricing and reimbursement decisions in rare diseases. See Additional file 1 for glossary of terms on
the core elements of value
PRINCIPLE 2: Pricing and reimbursement decisions should be founded
on the assessment of OMP value and adjusted to reflect other
considerations beyond product value
a) Reimbursement decisions should be based on the product value delivered
by an OMP as described in Principle 1
b) The price should, among other elements, be informed by considering
the magnitude of the product value in light of price-value precedents
for other specialist technologies and medicines
c) P&R decisions should reflect the value that the EU attributes to OMPs
through the incentives put in place to develop them
d) Beyond OMP value, P&R status should be modulated to reflect other
considerations, such as societal preferences, rarity, budget impact and
sustainability of innovation in rare diseases
e) In countries where cost-effectiveness is applied to assess value for
money, the incremental cost-effectiveness ratio (ICER) thresholds
should be modulated to reflect:
• all specificities of rare diseases (including rarity, unmet therapeutic
need and societal preferences)
• the need to maintain innovation in rare diseases
f) P&R decisions should aim at contributing to the right balance between
allowing sufficient revenue generation to incentivise new research
investment in rare diseases and attract private funders, while maximising
value for money for healthcare systems
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OMP under evaluation in respect to disease severity,
number of patients and product attributes [5].
Beyond the value of the OMP, other considerations
are relevant to P&R decisions, including the size of
the expected budget impact (across all approved indi-
cations, if more than one) and societal preferences
concerning the value of new treatments for a given
rare disease [30, 47, 54–56].
The size of the patient population for an authorised
treatment is an important consideration in P&R decision
making. Rarer diseases are associated with greater evi-
dential uncertainty compared with more common dis-
eases as there is less information on the natural history
of disease and smaller patient numbers in clinical trials
[57]. Rarity is therefore pertinent to the consideration of
the uncertainty around the value estimate. The size of
the patient population is also a major determinant of the
budget impact for payers and the revenue potential for
manufacturers and thus is directly relevant to the P&R
decision [7, 58]. OMP legislation was an explicit recogni-
tion that incentives to invest in developing treatments
for rare diseases are lower than for more common dis-
eases (a smaller patient population results in a lower po-
tential return on investment) [2, 59]. OMP pricing has
subsequently been observed to be correlated with dis-
ease prevalence, with higher per patient prices in the rar-
est diseases [60]. Studies of societal preferences for
funding treatments for rare diseases have not shown
clear support for prioritising rarity alone in P&R deci-
sions, however there is a preference for reducing in-
equalities in health outcomes [61–63]. Given that the
degree of rarity directly affects the financial incentive to
develop treatments in a given disease area, it is only pos-
sible to address health inequalities in small populations
if rarity is taken into account.
Cost effectiveness analysis (particularly when restricted
to a health service perspective) is not optimal for the
assessment of OMPs, as the QALY fails to account for all
of the core elements of value relevant to rare diseases
[49–51]. If it is to be used to inform assessments of
OMPs, the ICER thresholds should be modulated to re-
flect all the specificities of rare diseases as described in
Fig. 3. Countries that use strict and non-modulated ICER
thresholds to guide reimbursement decisions have a poor
record of approving OMPs (e.g. Canada) [49]. For OMPs
to be approved in systems using ICERs for decision
making, payers will need to adopt variable thresholds at
levels higher than that applied historically [14, 20].
In general, P&R decisions should balance the need to
enable revenue generation to incentivise new research
investment in rare diseases with the need to maximise
value for money for healthcare systems. But OMPs
prices should be such that all products that provide clin-
ically meaningful added benefits (i.e. that are approved
by the Committee for Orphan Medicinal Products
[COMP]/EMA) are commercially feasible and incentiv-
ise continued investment in rare diseases. At the same
time, the P&R decision must also consider the afford-
ability of the expenditure and be aligned with the sus-
tainability of healthcare system finances.
Principles on OMP decision process
To ensure consistency and alignment between
Member States, avoid duplication of evaluations, and
improve resource utilisation, P&R agencies should
build on the official decisions and recommendations
made for OMPs at a European level, tailoring and
adapting these assessments to their local environment.
Currently, the duplication of regulatory and HTA activities
at a national level contributes to the lengthy and often
variable access to OMPs across Member States [64].
Official decisions and recommendations include
the COMP’s assessment of significant benefit and
prevalence, the EMA’s European Public Assessment
Report (EPAR) and the relative effectiveness assess-
ments undertaken by the European network on
health technology assessment (EUnetHTA). Payers
should also account for early conditional and excep-
tional marketing authorisations as well as the early
scientific advice provided by the EMA. European le-
gislation recommends Member States use COMP/
EMA assessments to guide and align national deci-
sion making, helping build on existing, central regu-
latory European assessments.
This approach offers several benefits. European-level
health authorities have the greatest concentration of
rare-disease expertise and, importantly, COMP offers
specific rare disease guidance (conversely, national level
assessment authorities are typically more generalised).
This also ensures Member States can utilise clinical ex-
perts from the specialist centres across Europe [2, 4, 65].
Avoiding duplication of effort and reducing existing
asymmetries in assessments may improve resource util-
isation and, subsequently, reduce the time to OMP
decision-making.
PRINCIPLE 3: Those making P&R decisions about OMPs at a national
level should take account of all official regulatory and health
technology assessments of OMPs undertaken at the European level
a) National P&R agencies should build on the decisions and
recommendations at a European level, including:
• The Committee for Orphan Medicinal Products (COMP)’s assessment of
significant benefit and prevalence
• The EMA’s European Public Assessment Report and Summary of
Product Characteristics
• Relative effectiveness assessments undertaken by the European
network for HTA
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While there is a need to ensure national assessments
and decisions reflect the local population’s needs, there
is a strong argument that, in the case of rare diseases,
the centralised knowledge, data and expertise that is
pooled at the European level leads to stronger decision
processes than those restricted to information available
locally. Where central and national opinions differ, with
contradictory conclusions, there is a need to acknow-
ledge the importance of this and find consistency be-
tween assessments.
HCPs, patients (and their carers) should be involved
in the value assessment (HTA) and appraisal (P&R
decision making) of OMPs, offering an important
insight into the real-world experience of a rare dis-
ease [5, 29, 66–71]. The nature of rare diseases mean
that the involvement of patient and physician experts
is even more important than in assessments of treat-
ments for non-rare diseases. There is often limited in-
formation on the natural history and burden of a rare
disease, and current standard of care treatments may
be poorly established with little evidence of effective-
ness [72, 73]. These stakeholders can help authorities
understand what outcomes are relevant in a disease
and what level of improvement is clinically meaningful.
HCPs and patients have the expertise and experience to
discuss HRQoL, burden of disease and patient preferences
[67, 74, 75]. Clinical experts and patients may also
help interpret the relevance of trial data, where end-
points might be unusual or not validated in the disease in
question. They can help assessment authorities under-
stand why surrogate endpoints have been used and what
they mean [76, 77].
In addition to trial design interpretation, clinical
experts and patient groups can help inform estimates
of prevalence and potential patient uptake on treat-
ment. Patient associations have previously provided
very accurate estimates of patients (e.g. the MPS
Society for elosulfase alfa in the UK [78]). Experts
may also help to establish the natural history of the
rare disease, its symptomology and burden, in the
absence of observational data. For example, patient
interviews and surveys have been instrumental in es-
tablishing knowledge about the ways in which rare
diseases affect patients, their families and the costs
they impose on wider society [79]. Finally, patients
and HCPs can provide insights into the current pa-
tient treatment pathways and identify issues with
current treatments and expectations from new ther-
apies [69, 75, 77].
The involvement of HCPs and patients in value as-
sessment can be implemented in a variety of ways.
For example, disease-specific expert physicians (and
other relevant academic specialists) can input dir-
ectly into the assessment and appraisal process. Pa-
tients can be systematically represented in bodies
that assess and appraise OMPs as part of an over-
arching patient association. Disease-specific patient
representatives could be involved throughout the
process, provided that they have received appropriate
training and support to contribute fully. EUPATI
(the European Patient’s Academy) provides training
courses for patients with the aim of enhancing their
skills and enabling them to contribute to medicines
research and development. Such initiatives should be
supported and supplemented with process-specific
training at national levels [80].
To this end, clear, consistent guidelines should be
developed, enabling stakeholders (in particular patient
associations), to prepare submissions and be in a
position to respond to the appraisal process. For
example, generic patient group submission templates,
such as those developed by Health Technology
Assessment International (HTAi), can help patient
groups identify the type of information that HTA
agencies require in regard to patient and caregiver ex-
periences, living with the disease, its management and
unmet needs [81].
Given the nature of rare diseases, uncertainty is inher-
ent in all elements of product value. When assessing
value, payers should consider this uncertainty in light of
the disease prevalence and the level of existing know-
ledge and evidence about the disease. Typically, rare dis-
eases with the lowest prevalence are associated with
greater uncertainty compared with rare diseases with a
higher prevalence [20].
At the time of launch, it should be recognised that,
due to the size of the patient population and limited nat-
ural history data, there will often be incomplete informa-
tion to provide certainty around the long-term clinical
benefit and overall value of a new OMP [57]. In those
cases there will be a need for a continuum of evidence
PRINCIPLE 4: The assessment and appraisal of OMPs to inform
national P&R decisions should incorporate rare disease expertise
including both the healthcare professionals’ (HCP) and patients’
perspectives
a) HCPs and patients and their carers should be involved in the value
assessment in the following ways:
• Disease-specific expert physicians (and other relevant academic
specialists) should be involved from scoping of an assessment
through to appraisal determination by the bodies that assess and
appraise OMP
• Systematic representation of patient associations in meetings that
assess and appraise OMPs
• Disease-specific patient representatives should be involved throughout the
process and given appropriate training and support to
contribute fully
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generation. Further data collection will often be required
post-launch to enhance the understanding of the clinical
benefit and the overall value and to reduce uncertainty.
Systematically collecting data from registries as well as
implementing managed access schemes (where possible)
could help mitigate the uncertainties and fill data gaps.
This need for incremental evidence generation has been
recognised through conditional approval regulatory pro-
cesses [82].
Value assessment processes need to be adaptive (i.e.
contingent) where necessary and continuous, rather than
binary at the point of launch. An adaptive value assess-
ment process would take into account the nature of the
R&D challenge in rare diseases. Furthermore, it would
contribute to better access to treatments for patients
and would allow the building of evidence in clinical
practice. P&R decisions may also be adaptive (i.e. in-
creased or decreased) based on the data provided. While
there are precedents for adaptive P&R mechanisms in
Europe, there is some scepticism about their effective-
ness historically (from both payers and industry) and a
need for more robust design and implementation in
future [10, 83].
Adaptive pathways to OMP assessment have been in-
creasingly mentioned in recent policy debates and have
been piloted at the European level [84]. Where adaptive
processes are required, a framework for shared agreement
between stakeholders should be developed to identify key
responsibilities of all parties. Data collected should be
independently validated and reviewed to maintain
objectivity.
There has been a trend towards payers mandating
country-specific registries (e.g. Germany, UK, France) to
support conditional reimbursement decisions for OMPs
with different data variables collected [64]. Where pos-
sible, the collection and analysis of real-world data
should be co-ordinated at a European level and should
be integrated in disease level registries and databases to
obtain more consistency in the continuous assessment
and appraisal of OMPs. This requires common defini-
tions of outcomes to be collected as well as uniform sets
of standards to guarantee data quality and completeness.
It is essential to ensure that the duties and rights of
every party involved in real-world data collection are
respected. Therefore, financial responsibilities for col-
lecting registry data should be shared proportionally be-
tween interested stakeholders as per the EUCERD
recommendation on rare disease patient registration
[85]. There should be the option to supplement this data
with additional information that may be specific to
Member States. EUnetHTA has notably put in place a
common core protocol for Additional Evidence Gener-
ation (AEG) to set out the methodological basis for
European cooperation in this field [86].
Estimating the likely budget impact of OMPs is a key
challenge for payers [47, 55]. The greatest uncertainty in
estimating budget impact concerns the number of pa-
tients who will receive treatment. This uncertainty stems
from the challenges of estimating prevalence as a result
of the poor diagnosis of rare disease patients and the
lack of expertise in these diseases. Local prevalence data
is often inadequate and there is an opportunity to reduce
uncertainty through the pooling of epidemiological data
at the European level. However, coherent systems are
necessary to facilitate this collaboration between Mem-
ber States and to allow for the co-ordination of post-
launch data collection.
In advance of product launch, manufacturers,
payers, HTA agencies, centres of expertise and Euro-
pean reference networks should collaborate to collect
data on the true prevalence of a given rare disease in
order to minimise financial uncertainty for payers.
Such early collaboration will also ensure development
of adequate capabilities for large scale post-launch
data collection.
The heterogeneous nature of rare diseases and
small patient populations make it difficult to collect
extensive data [57]. For ethical reasons, it may not
be possible to generate data from certain subgroups
of populations (e.g. children) who are often affected
by rare diseases, but may not be allowed to
PRINCIPLE 5: To accommodate uncertainty, value assessment and
pricing and reimbursement decisions should be adaptive subject
to the need and availability of information over time
a) Given the nature of rare diseases, there is inherent uncertainty around
all elements of product value. When assessing value, payers should
consider this uncertainty in light of:
• disease prevalence
• disease severity and unmet need
• amount of prior research conducted in the disease
• extent to which the manufacturer has taken reasonable steps to
minimise uncertainty
b) To account for clinical and economic uncertainty, value assessment
processes need to be adaptive (i.e. contingent), where necessary, and
continuous rather than binary at the point of launch
c) Pricing and reimbursement decisions should allow movement both
up and down with newly generated evidence on value
d) Where adaptive processes are required, all parties (payers, HTA
agencies, involved HCPs, patients and industry) need to agree on this
iterative process and clearly document the following:
• the evidence required and milestones for each step of the assessment
• the implications of not meeting the requirements and expectations
initially agreed
• each stakeholder’s shared responsibility to collect and evaluate the data
e) Where possible, the collection and analysis of real-world data should
be co-ordinated at a European or international level and should be
integrated in disease level registries and databases:
• to obtain more European consistency in the continuous assessment
and appraisal of OMPs
• to collect data on the true prevalence of a given rare disease in order
to minimise financial uncertainty for payers
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participate in clinical trials [87]. Wherever possible,
reimbursement decisions should seek to ensure that
all patients specified in the product marketing au-
thorisation should receive access to treatment. This
should take into consideration how the uncertainty for
a proportion of the population can be better ad-
dressed. This may be in the form of an adaptive path-
way or managed access program.
Data usually does not allow for sub-grouping in a
way that is statistically or clinically credible. However,
where there is a broad spectrum of disease, and the
financial impact of treatment is very high, it is rea-
sonable to consider this in P&R decisions across
patient subgroups.
Principles on OMP sustainable funding systems
Funding for OMPs should be co-ordinated at a national
level in order to avoid disparities in access between re-
gions and to pool the financial risk of irregular distribu-
tion of patients across geographies. Where reimbursement
decisions have been left to regional bodies, variance in
access has been observed (e.g. Sweden, Italy) [8, 88, 89].
Due to the genetic nature of many rare diseases, the
burden of payment may be concentrated in one area; a
national risk-sharing scheme would overcome regional
disparities in disease presentation.
In order to facilitate this, regional and local funding
bodies should liaise and cooperate with national author-
ities to avoid inconsistencies and inequalities in regional
access. Regional funding bodies should be represented
within national bodies, ensuring funding decisions taken
at this level are quickly implemented locally.
It is preferable that funding for OMPs should come out
of normal healthcare budgets as opposed to ear-marked
rare disease funds that do not allow for a long-term per-
spective. Ear-marked disease-specific funds are seen in
countries such as Scotland [90], Italy [91] or in England
with the Cancer Drug Fund [92]. These tend to be subject
to political revision and can be arbitrary in value.
Manufacturers, payers and HTA agencies should collab-
orate nationally to improve forecasting and cooperate at
the European level for horizon scanning. Such collaboration
should aim to help budget holders predict and plan for
expenditure and ensure adequate funding of OMPs. One of
the primary concerns of payers regarding OMPs is the
long-term sustainability of funding [5, 17]. To ensure fund-
ing is sustainable, payers need to model beyond annual
budget cycles to forecast the total expenditure on OMPs,
including likely savings as older products lose marketing
exclusivity. In addition to budget impact forecasting, payers
should look beyond the total expenditure on an OMP to
include cost offsets from reduced medical resource use
resulting from the introduction of the OMP. Manufacturers
should collaborate with payers in this process, providing
timely information on products under development, label
expansions and expected launch dates, as well as aiding in
the estimation of potential cost-offsets. Horizon scanning
efforts can be co-ordinated at a European level, as the core
information on the number of products likely to be
approved is common across European countries.
Principles on OMP European co-ordination
While recognising that the reality today is one of
national level competence, there is potential for a greater
level of co-ordination at the European level with regards
to certain elements of value assessment. Rationales for
collaboration between Member States on value assess-
ment could include guarantees about greater consistency
in the definition and assessment of clinical value, greater
concentration of clinical expertise, pooling of data on
epidemiology, opportunities for more systematic collec-
tion and assessment of data, and reduced duplication of
effort at the national level in the re-assessment of value
Principles 6: All eligible patients within the authorised label of an
OMP should be considered in the national P&R decision although
different decisions on access may apply to different sub-populations
a) Wherever possible, reimbursement decisions should seek to ensure
that all patients specified in the product marketing authorisation
should receive access to treatment
b) Reimbursement may be reflective of situations where there is a broad
spectrum of disease and clearly defined patient subgroups in which
OMP value substantially differs
PRINCIPLE 7: Funding should be provided at the national level to
ensure patient access to OMPs
a) Funding for OMPs should be co-ordinated at a national level in order
to avoid disparities in access between regions and to pool the financial
risk of irregular distribution of patients
b) Regional and local funding bodies should liaise and cooperate with
national authorities to avoid inconsistencies and inequalities in regional
access
c) It is preferable that funding for OMPs should come out of normal
healthcare budgets rather than from ear-marked rare disease funds
that do not allow for a long-term perspective
PRINCIPLE 8: Evidence-based funding mechanisms should be
developed to guarantee long-term sustainability
a) Manufacturers, payers and HTA agencies should collaborate nationally
to improve forecasting and cooperate at the European level for
horizon scanning with the aim of helping budget holders predict and
plan for expenditure and ensure adequate funding of OMPs
b) Early stage dialogue should occur between all stakeholders to ensure
long term sustainability of outcomes
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and as such, faster access to medicines for patients.
The benefits of establishing European Reference net-
works for rare diseases has been widely recognised [93],
notably by overcoming the limited experience of profes-
sionals confronted with rare disease and by improving
access for EU citizens to treatment requiring a particu-
lar concentration of resources or expertise. The future
European collaboration on Relative Effectiveness As-
sessments, which is currently launching pilots within
EUNetHTA’s Joint Action 3 [94] and planning to be for-
malised in 2019, is a key step forward towards this
needed collaboration.
Conclusion
The advent of European OMP legislation and subse-
quent growth in new authorised treatments represents
an important opportunity to improve human health and
redress the years of under-investment in rare disease
treatments. To be successful, this goal requires the
maintenance of incentives that have stimulated invest-
ment in European rare disease research with subsequent
benefits for the wider scientific economy [95]. It also re-
quires further development of P&R processes to improve
patient access to new medicines and provide greater
clarity to those who would invest in future research in
rare diseases.
There are many challenges to quick and comprehen-
sive patient access to OMPs [5, 47]. In addition to the
technical issues of imperfect information, evidential and
financial uncertainty, evolving regulatory pathways and
novel scientific platforms, are the more general concerns
of lack of mutual understanding between payers and
OMP manufacturers. Greater consistency of processes
between Member States, clear criteria for the assessment
of value and value for money, increased transparency
and clarity about decisions, and more collaboration and
information sharing between payers and manufacturers
could help address these challenges.
The principles outlined in this paper may be helpful in
drawing together an emerging consensus on this topic
and identifying areas where consistency in payer ap-
proach could be achievable and beneficial. These princi-
ples recognise that P&R is a national competency, as
there needs to be flexibility for payers to reflect local
societal preferences. They do not seek to specify the
process that payers use to make P&R decisions, but to
ensure a common underlying approach and convergence
around core concepts. Future research might seek to
explore on a country-by-country basis the areas in which
existing value assessment and P&R frameworks align
with these principles and where there is divergence, as a
stimulant for policy appraisal. Identifying differences be-
tween the principles and current systems will stimulate
further discussions on the practical changes and ways to
implement the principles.
The formulation of the principles has been informed
by evidence wherever possible, but ultimately these rec-
ommendations represent the opinion and experiences of
those experts involved in the development, regulation,
assessment and use of OMPS in Europe. As such, they
are fundamentally subjective. These principles are likely
to stimulate the current debate regarding cooperation
between HTA agencies in Europe, and to inspire future
research to better document what can be achieved to
improve a fair assessment of OMPs and a fair utilisation
of this assessment by the decision-makers.
The need for greater consistency, clarity and cer-
tainty will become ever more important as the number
of OMPs grows. Yet, while there are still many thou-
sands of rare diseases for which no effective treat-
ments exist, all stakeholders – payers, policy makers
and manufacturers – will need to take a long-term
perspective and build frameworks and processes that
are capable of addressing the scale of the challenge.
Ultimately, OMPs offer the potential to improve equity
of access to effective treatment for the biologically
least advantaged in our communities. All stakeholders
have an obligation to work together to ensure that this
promise is realised.
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